Skip to main content

Charles River Laboratories Value Stock - Dividend - Research Selection

Charles river laboratories international

ISIN: US1598641074 , WKN: 939391

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Molten leads EUR 31 million Series C In Deciphex

2025-01-07
Molten is pleased to announce it has led a EUR 31 million Series C in Deciphex a leader in AI-powered digital pathology.Led by Molten Ventures with significant participation from ACT Venture Capital,...

Should You Retain Charles River Stock in Your Portfolio Now?

2025-01-02
CRL's solid prospects in the RMS segment and solid financial stability create a favorable outlook for investors.

Fortrea: Turning Around As The Activists Move In

2024-12-26
Fortrea, a recent Labcorp spin-off, is poised for recovery with strong bookings, industry inflection, and activist interest, despite a 46% stock drop in 2024. Read more here.

Earnings are growing at Charles River Laboratories International (NYSE:CRL) but shareholders still don't like its prospects

2024-12-19
Investing in stocks inevitably means buying into some companies that perform poorly. But the last three years have been...

Tracking John Rogers' Ariel Investments Portfolio - Q3 2024 Update

2024-12-17

ICON: A High Probability Of Success In The Uncertain R&D Process

2024-12-13
ICON Public Limited Company experiences short-term challenges but has solid long-term prospects. See why ICLR stock is a compelling buy at current valuations.

Allspring Special Mid Cap Value Fund Q3 2024 Commentary

2024-12-12
The fund underperformed the Russell Midcap Value Index during the third quarter of 2024. Click here to read the full commentary.

Why Is Charles River (CRL) Down 8.9% Since Last Earnings Report?

2024-12-06
Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

CRL Stock to Gain From the Global Biotech Incubator Program Launch

2024-12-06
Charles River's new initiative specifically caters to early-stage biotechnology developers.

Charles River Introduces Global Biotech Incubator Program

2024-12-05
WILMINGTON, Mass., December 05, 2024--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of the Charles River Incubator Program (CIP), specializing in supporting early-stage biotechnology companies in the discovery, development and phase-appropriate manufacturing of advanced therapies.